Non-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes Mellitus
Launched by KING SAUD UNIVERSITY · Jan 15, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying non-alcoholic fatty liver disease (NAFLD) in people with type 2 diabetes in Saudi Arabia. NAFLD is a condition where fat builds up in the liver without alcohol being the cause, and it has become more common due to rising obesity rates. Researchers want to understand how this disease develops over time in patients with type 2 diabetes and to identify possible markers that can help determine how severe the disease is. They will follow 1,000 adult participants for up to 10 years, checking their diets, body measurements, and conducting various tests to see how many develop NAFLD and how their metabolism changes.
To be eligible for the study, participants must be between 18 and 60 years old and diagnosed with type 2 diabetes. Those with certain liver problems or serious heart issues will not be included. Participants can expect to undergo several assessments over the years, which will help researchers gather important information about NAFLD's impact on health in the local community. This study aims to raise awareness about the seriousness of NAFLD and improve public health strategies in Saudi Arabia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject has provided informed consent prior to screening
- • Men and women aged 18 to 60 years
- • T2DM
- Exclusion Criteria:
- • Evidence of hepatic decompensation (ascites, clinical jaundice-bilirubin ≥ 40 µmol/L, encephalopathy)
- • Preexisting hepatocellular carcinoma
- • Other preexisting hepatic or extrahepatic malignancy
- • Previous overt ischemic heart disease (myocardial infarction or acute coronary syndrome) or cerebrovascular disease (stroke or transient ischemic attack)
- • Previous coronary artery bypass grafting, angioplasty, or stenting
- • Any other issues that, in the opinion of the investigators, may preclude satisfactory completion of the study protocol
About King Saud University
King Saud University (KSU), established in 1957, is a leading higher education institution in Saudi Arabia, renowned for its commitment to advancing research and innovation in various fields, including health sciences. With a robust infrastructure and a diverse pool of expert faculty, KSU actively engages in clinical trials aimed at improving healthcare outcomes and addressing pressing medical challenges. The university prioritizes ethical research practices and collaboration with local and international partners to contribute to the global body of medical knowledge, ultimately enhancing patient care and public health in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riyadh, , Saudi Arabia
Riyadh, Select A State Or Province, Saudi Arabia
Patients applied
Trial Officials
Assim Alfadda, MD
Principal Investigator
King Saud University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials